TY - JOUR
T1 - Recommendations for the Use of Mechanical Circulatory Support
T2 - Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association
AU - Cook, Jennifer L.
AU - Colvin, Monica
AU - Francis, Gary S.
AU - Grady, Kathleen L.
AU - Hoffman, Timothy M.
AU - Jessup, Mariell
AU - John, Ranjit
AU - Kiernan, Michael S.
AU - Mitchell, Judith E.
AU - Pagani, Francis D.
AU - Petty, Michael
AU - Ravichandran, Pasala
AU - Rogers, Joseph G.
AU - Semigran, Marc J.
AU - Toole, Matthew M.
AU - On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Coun
N1 - Publisher Copyright:
© 2017 American Heart Association, Inc.
PY - 2017/6/20
Y1 - 2017/6/20
N2 - Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80%, and 2-year survival, 70%.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.
AB - Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80%, and 2-year survival, 70%.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.
KW - AHA Scientific Statements
KW - ambulatory care
KW - congestive heart failure
KW - emergency care
KW - emergency first responders
KW - ventricular assist device
UR - http://www.scopus.com/inward/record.url?scp=85020113658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020113658&partnerID=8YFLogxK
U2 - 10.1161/CIR.0000000000000507
DO - 10.1161/CIR.0000000000000507
M3 - Article
C2 - 28559233
AN - SCOPUS:85020113658
SN - 0009-7322
VL - 135
SP - e1145-e1158
JO - Circulation
JF - Circulation
IS - 25
ER -